Pharmaceutical

Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia

Alemtuzumab, under the brand name Campath, was pulled from the leukaemia market by Sanofi in 2012.

Aug 3, 2024 - 04:00
Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia
Alemtuzumab, under the brand name Campath, was pulled from the leukaemia market by Sanofi in 2012.
Read the original article

Tags:

Previous Article

Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy

Next Article

Rejuvenate and SAS partner to harness AI for age-related diseases

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer

Pfizer and Genmab’s Tivdak wins full FDA approval for c...

May 1, 2024

STAT+: Raleigh-Durham challenges Boston as biomanufacturing hub of the future

STAT+: Raleigh-Durham challenges Boston as biomanufactu...

Feb 1, 2024

Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency d...

Aug 31, 2024